Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.
Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.
Patients with multiple myeloma have seen their survival rate strongly improved with the use
 of new anti angiogenic agents. Among them, the new chemotherapy with thalidomide or
 lenalinomide are frequently successfully suggested in therapeutic protocol such as MPT
 however they can strongly increase the risk of venous thrombo embolic disease (DVT and PTE)
 up to 20%. In these conditions, a prevention of this risk can be proposed by physician with
 either low molecular weight heparin (LMWH) anticoagulants or antiplatelets agents. Pending
 the new recommendations on the management of VTED, the purpose of this study is to describe
 in real life conditions the management by oncologists of the thrombo embolic risk for such
 patients
Inclusion Criteria:

 -  Patients with multiple myeloma receiving a chemotherapy protocol including thalidomide
 or lenalidomide

 Exclusion Criteria:

 -  Patients involved in an interventional clinical trial